Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548470 · ClinicalTrials.gov registry record · Phase 4
Varenicline Effects In Schizophrenic Smokers
A Phase 4 study of Schizophrenia and Tobacco Use Disorder, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00548470 is a Phase 4 study of Schizophrenia and Tobacco Use Disorder that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 14 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00548470, a Phase 4 study of Schizophrenia and Tobacco Use Disorder, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).
Conditions Studied
Interventions
- DRUG Varenicline
Study Locations (1)
New York
- Manhattan Psychiatric Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548470
The ClinicalTrials.gov registry entry for NCT00548470 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (94% lower). The listed sponsor is Nathan Kline Institute for Psychiatric Research, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Varenicline is the first listed.
NCT00548470 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00548470 about?
NCT00548470 is a clinical study titled "Varenicline Effects In Schizophrenic Smokers". This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and...
What is the current status of trial NCT00548470?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2007-06. Estimated completion is 2010-12.
What conditions does trial NCT00548470 study?
This clinical trial studies the following conditions: Schizophrenia, Tobacco Use Disorder, Nicotine Dependance.
What interventions are being tested in trial NCT00548470?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT00548470?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00548470 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.